Healthcare & Pharma
The Healthcare & Pharma sector encompasses 15 tracked companies carrying $265.3B in combined long-term debt. Across the sector, $34.5B (7% of maturities) is due within the next 12 months. The majority of obligations ($316.3B) extend beyond five years, providing longer-term refinancing runway.
Companies in Sector
15
Total Sector Debt
$265.3B
High Risk
0
Avg Risk Score
2.9
| Company | Risk Score | Total Debt | 12mo Due |
|---|---|---|---|
|
Amgen
AMGN |
5/10 Medium Risk | $57.3B | $4.6B |
|
Bristol Myers Squibb
BMY |
5/10 Medium Risk | $44.1B | $2.0B |
|
Pfizer
PFE |
5/10 Medium Risk | N/A | $3.9B |
|
AbbVie
ABBV |
4/10 Medium Risk | $64.5B | $6.0B |
|
Cvs Health
CVS |
4/10 Medium Risk | N/A | $4.0B |
|
Zoetis
ZTS |
4/10 Medium Risk | N/A | $750M |
|
Merck &
MRK |
3/10 Low Risk | N/A | $2.6B |
|
Unitedhealth Group
UNH |
3/10 Low Risk | N/A | $6.1B |
|
Cigna Group
CI |
2/10 Low Risk | N/A | $550M |
|
Gilead Sciences
GILD |
2/10 Low Risk | $22.2B | $1.3B |
|
Johnson & Johnson
JNJ |
2/10 Low Risk | $41.4B | $2.0B |
|
Eli Lilly
LLY |
2/10 Low Risk | $29.5B | $781M |
|
Biogen
BIIB |
1/10 Low Risk | $6.3B | $0 |
|
Regeneron Pharmaceuticals
REGN |
1/10 Low Risk | N/A | N/A |
|
Vertex Pharmaceuticals Inc / Ma
VRTX |
1/10 Low Risk | N/A | N/A |